US5985319A - Multi-phase compositions for an initial and delayed release of a vaginal medicament - Google Patents

Multi-phase compositions for an initial and delayed release of a vaginal medicament Download PDF

Info

Publication number
US5985319A
US5985319A US08/605,070 US60507096A US5985319A US 5985319 A US5985319 A US 5985319A US 60507096 A US60507096 A US 60507096A US 5985319 A US5985319 A US 5985319A
Authority
US
United States
Prior art keywords
composition
metronidazole
pessary
vaginitis
medicament
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
US08/605,070
Inventor
Koral Embil
Oswald Morton
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Edko Trading and Representation Co Ltd
Original Assignee
Edko Trading and Representation Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Edko Trading and Representation Co Ltd filed Critical Edko Trading and Representation Co Ltd
Assigned to EDKO TRADING AND REPRESENTATION COMPANY LIMITED reassignment EDKO TRADING AND REPRESENTATION COMPANY LIMITED ASSIGNMENT OF ASSIGNORS INTEREST (SEE DOCUMENT FOR DETAILS). Assignors: EMBIL, KORAL, MORTON, OSWALD
Application granted granted Critical
Publication of US5985319A publication Critical patent/US5985319A/en
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0034—Urogenital system, e.g. vagina, uterus, cervix, penis, scrotum, urethra, bladder; Personal lubricants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/415—1,2-Diazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1635—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates

Definitions

  • This invention concerns novel pharmaceutical compositions for combating vaginal infections.
  • a pessary it is desirable for a pessary to be able to treat all the common forms of vaginitis, which are most often caused by infection with Candida albicans, Trichomonas vaginalis or Gardnerella sp, either singly or mixed.
  • Commonly derivatives of imidazole and nitroimidazole are used to treat such conditions, examples of such drugs being miconazole, clotrimazole, ornidazole, tinidazole and metronidazole, but despite the good activity of these compounds none has so far individually achieved the broad spectrum of activity required to combat all the common types of infection.
  • Other types of drugs used in such infections include nitrofurfuryl derivatives and various antibiotics.
  • the half life of most anti-vaginitis medicaments is generally relatively short, for example six hours, and it is difficult to formulate a medicament which can effectively be administered only once a day.
  • it is preferable to provide a relatively large booster dose of the active substance so that a delayed release formulation is not entirely satisfactory.
  • levels of the active substance tend to fall towards the end of the period, for example 24 hours, so that a booster dose may be desirable at intervals during medication.
  • multiphase formulations comprising a continuous phase containing a relatively large amount of one or more anti-vaginitis medicaments for relatively rapid initial release and containing, dispersed therein, microporous particles containing one or more of the anti-vaginitis medicaments and releasing these over a prolonged period, for example 24 hours.
  • a pharmaceutical composition for the treatment of vaginitis comprising a continuous phase containing one or more anti-vaginitis medicaments for rapid release and porous particles dispersed therein adapted for delayed release of one or more anti-vaginitis medicaments.
  • the phase in which the medicament(s) are contained may be a conventional cream base, e.g. containing oily or waxy materials such as liquid paraffin, white petroleum or cetyl alcohol, water and one or more surfactants to produce a water-in-oil emulsion.
  • a bactericide such as benzalkonium chloride is conveniently present.
  • compositions take the form of pessaries comprising a pessary base containing the anti-vaginitis medicament(s) and porous particles for delayed release of anti-vaginitis medicament(s).
  • the pessary base may be of any conventional material for vaginal administration such as glycerol/gelatin glyco-gelatin, macrogols (polyethylene glycols), natural, synthetic or semisynthetic hard fats, and fractionated palm kernel oil.
  • a particularly preferred material is a hard fat such as cocoa butter (theobroma oil), for instance the range of cocoa butter-based products sold under the trade name Witepsol by Dynamit Nobel, Slough, England.
  • the pessary base may conveniently contain a surfactant to promote dispersal of the active substances. It may also be advantageous to include a surfactant in the porous particles to aid release of the medicament therein and to promote continuous penetration of the active substances into the mucosal folds.
  • the surfactant may be a cationic, non-ionic, anionic or amphoteric surfactant although non-ionic surfactants are preferred.
  • Anionic surfactants include salts of long chain alkyl sulphonate esters such as sodium lauryl sulphate, sodium cetostearyl sulphate and sodium tetradecyl sulphate; salts of long chain carboxylic acids such as stearates.
  • Cationic surfactants include quaternary ammonium or pyridinium compounds such as benzalkonium chloride (a mixture of benzyl alkyl dimethyl chlorides, the alkyl chain ranging from C 8 to C 18 ), tetradecyltrimethyl ammonium bromide and cetylpyridinium chloride.
  • benzalkonium chloride a mixture of benzyl alkyl dimethyl chlorides, the alkyl chain ranging from C 8 to C 18
  • tetradecyltrimethyl ammonium bromide and cetylpyridinium chloride.
  • Amphoteric surfactants include lauryl 1-carboxy glycine and lecithins such as soya lecithin.
  • Non-ionic surfactants include glycol and glycerol esters such as glyceryl monostearate; macrogol esters and ethers such as cetomacrogol; sorbitan and mannitan esters such as sorbitan tristearate; and polyoxyethylene derivatives of such sorbitan esters, for instance polyoxyethylene (20) sorbitan mono-oleate.
  • the level of surfactant required in the pessary formulation will be readily determined by those skilled in the art and will depend on the specific surfactant and the nature of the pessary base; conveniently it is in the range 0.1 to 10 percent by weight, preferably 1 to 5 percent.
  • a cetomacrogol surfactant in conjunction with a cocoa-butter base such as Witepsol.
  • the surfactant is suitably present in the range 1 to 5 percent by weight, for instance about 40 mg in an overall pessary weight of 2540 mg (including active ingredients).
  • the active substances should include at least one medicament active against Trichomonas vaginalis.
  • one aspect of the invention provides a pessary for human administration comprising an effective amount of one or more drugs active against Trichomonas vaginalis, a pessary base and a surfactant.
  • the preferred antitrichomonal drug is metronidazole.
  • a surfactant according to the invention allows the active antitrichomonal drug fully to penetrate between the apposed layers of vaginal epithelium which occur in the rugose surface of the vagina so reaching the Trichomonas sp. which otherwise would be protected by such apposition from contact with the active ingredients of conventional pessary formulations.
  • the relapse rate when treatment ceases can therefore be expected to be lower than when metronidazole is administered intravaginally in a conventional pessary formulation.
  • fungicidally active derivative of nitroimdazole such as butoconazole or, more preferably, miconazole, is advantageously used as the drug active against Candida albicans.
  • Ornidazole, Ketoconazole, Tioconazole and Tinidazole are also suitable fungicidally active agents. Where metronidazole is used as the antitrichomonal drug, it will also be effective against Gardnerella sp.
  • a broad spectrum antibiotic such as pivampicillin or Clindamycin may advantageously also be included.
  • a broad spectrum antibiotic such as pivampicillin or Clindamycin may advantageously also be included.
  • a steroidal or non-steroidal antiinflammatory drug such as hydrocortisone or ibuprofen.
  • Lactic acid may also advantageously be included as a further active ingredient.
  • the pessaries of the present invention may also advantageously include chlorophyll as a deodorant.
  • chlorophyll as a deodorant. We have found that although some staining of clothes by the green coloration of the chlorophyll may take place, the surfactant in the composition ensures that such stains are readily removed.
  • the quantity of metronidazole is conveniently from 500 to 1500 mg per pessary, more preferably from 800 to 1200 mg and suitably about 1000 mg.
  • the pessary may conveniently contain from 200 to 600 mg of miconazole, more preferably from 240 to 480 mg.
  • the miconazole may be in the form of the free base, especially in the porous particles, or as a salt, for instance the nitrate, especially in the pessary base--a suitable quantity of miconazole per pessary is then about 400 mg.
  • the porous particles containing anti-vaginitis medicaments may contain two or more such medicaments and/or the composition may contain mixtures of porous particles each containing a different medicament or mixtures of medicaments.
  • the total pore volume is preferably in the range 0.1 to 2.0 ml/g, more preferably 0.3 to 1.0 ml/g.
  • the diameters of the particles will generally be in the range 1 to 1000 microns, preferably 5 to 100 microns, more preferably 10 to 50 microns: the surface area of the particles will generally range from about 1 to 500 m 2 /g, preferably 20 to 200 m 2 /g.
  • the porous particles may be composed of a wide range of materials. Many organic, synthetic polymers are suitable, as well as natural substances such as cellulose or gelatin. The choice of material will depend in part on the intended means of delayed release of the active medicament, i.e. diffusion, compression, dissolving or melting.
  • the porous particles may be relatively rigid. This has the advantage that the outermost pores do not collapse when the medicament diffuses out and thus do not block the diffusion of the medicament from the inner pores.
  • Such rigidity can be controlled by the degree of cross-linking of polymeric materials of which the particles are composed.
  • the degree of cross-linking will generally be at least 10%, more usually in the range 20 to 80%, for example 25 to 60%.
  • Polymers of which the particles may be formed include polyolefins, including polyethylene, polystyrene, polydicyclopentadiene etc.; polyacrylate esters, e.g. optionally alkoxylated C 1-10 alkyl, cycloalkyl, aryl or aralkyl esters of polyacrylic or polymethacrylic acids; polyvinyl esters e.g. polyvinyl acetate or polyvinyl laurate; polyvinyl ketones, e.g. polyvinylmethyl ketone; and polyvinyl ethers, e.g. polyvinylpropyl ether.
  • polyolefins including polyethylene, polystyrene, polydicyclopentadiene etc.
  • polyacrylate esters e.g. optionally alkoxylated C 1-10 alkyl, cycloalkyl, aryl or aralkyl esters of polyacrylic or polymethacrylic acids
  • the porous particles in such a cream may liberate the active medicament by diffusion, pressure, dissolving or melting. It is preferred that the particles are elastically compressable so that after first application of the cream whereby the medicament contacts the infected area, application of gentle pressure, for example by rubbing, causes rapid release of the active medicament to provide a coating of medicament over the layer of cream.
  • Elastically compressable particles may be composed of elastomers, such as those described in U.S. Pat. No. 4,873,091, including for example, isoprene rubbers, butadiene rubbers, chloroprene rubbers, styrene butadiene. Particularly useful are ethylene-propylene-diene terpolymers, wherein the diene components may be straight chain diolefins, cyclic dienes and bicyclic dienes. Examples of such dienes include 1,4-hexadiene, dicyclopentadiene and ethylidene norbornene. Silicone rubbers may also be used.
  • Porous particles which dissolve, primarily in aqueous body fluids may be composed of water-soluble gels including gelatin, agarose etc and certain polymethyl methacrylates such as Eudragit (Rohm, Darmstadt) which dissolve at the pH of the vagina.
  • Porous particles which melt may be composed of fats and waxes of the type used in suppositories which melt at body temperatures but which are solid at room temperature as well as gelatin.
  • Porous materials for use in compositions of the invention may be made in any convenient way.
  • the active medicament can then be absorbed into the porous material, if desired by first evacuating air from the pores.
  • the active medicament can, however, itself be used as the porogen: the medicament may be dispersed in droplets through a monomer with which it is immiscible so that after polymerisation the active medicament effectively fills pores within the polymeric material.
  • porous particles may conveniently be produced by emulsion or suspension polymerisation in a liquid--liquid system.
  • a solution comprising the chosen water-immiscible monomer, any cross-linking agent required, a catalyst, if needed, and a porogen which is miscible with the solution but immiscible with water.
  • the solution is then suspended in an aqueous solution, which may contain one or more suspending agents or surfactants and polymerisation is initiated e.g. by raising the temperature or by irradiation.
  • the porogen is then removed from the solidified particles, e.g. by evaporation or extraction into a solvent which is substantially inert to the polymer.
  • porogens examples include C 5-12 alkanes, C 5-8 cycloalkanes and aromatic solvents such as benzene toluene etc.
  • the particles will normally be washed thoroughly to remove contaminants, using solvents such that the final solvent can be removed by evaporation.
  • particle diameter may be controlled by the degree of agitation to prepare the initial emulsion.
  • the pore diameter and pore volume are controlled by the amount of porogen used and the degree of cross-linking.
  • the monomers used to prepare the particles may be any of those appropriate to make the polymers set out above.
  • Suitable cross-linking agents for mono-olefins include poly-ethylenically unsaturated monomers.
  • the dosage of active medicament(s) contained in the porous particles will vary with the individual medicaments and their half-lives.
  • the ratio of delayed release medicament to rapid release medicament is preferably in the range 1:1 to 5:1, for example 2:1 to 4:1.
  • the porous particles may be evenly distributed throughout the composition or, in the case of pessaries, may be concentrated in one or more zones, for example in a core.
  • the size of the porous particles is preferably such that they cannot be taken up into the lymph ducts. On the other hand, large particles give a gritty effect which may produce discomfort. In general, the preferred size range for the porous particles is 10-100 microns.
  • the two active ingredients and the surfactant of the base are mixed into the molten Witepsol w35 and the resulting mixture is blended with the pre-prepared porous beads before being poured into pre-cooled moulds.
  • the moulds are passed through a cooling tunnel at -10° C., the pessaries are removed from the moulds and packaged. 0.1% by weight of chlorophyl may be added to both base and microsponge phases.
  • MONATERIC is a surfactant available from Mono Industries Ltd., Paterson, N.J., U.S.A.
  • the pessary is prepared according to the method of Example 1.
  • the MONATERIC 951A may be replaced by MONAQUAT PT-C, PT-L, PT-S or Phospholipid EFA.
  • the oily phase comprising the liquid paraffin, white petrolatum, cetyl alcohol and Span 60 are mixed at 60° C.
  • the aqueous phase comprising the remaining components except the porous beads is also blended at 60° C. and the two phases combined and homogeneously blended.
  • the porous beads are added subsequently and dispersed throughout the cream.
  • the pessary is prepared according to the method of Example 1.

Landscapes

  • Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Veterinary Medicine (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Gynecology & Obstetrics (AREA)
  • Reproductive Health (AREA)
  • Urology & Nephrology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)

Abstract

The present invention relates to multi-phase compositions for treating vaginal infections, for example, infections caused by Trichomonas vaginitis. The compositions, which are preferably formulated as a cream or pessary, comprise a continuous phase containing anti-vaginitis medicament for rapid, initial release and porous particles adapted for the delayed release of anti-vaginitis medicaments. Metronidazole is the preferred anti-trichomal medicament.

Description

This application is a 371 of PCT/GB94/01950 filed Sep. 8, 1994.
This invention concerns novel pharmaceutical compositions for combating vaginal infections.
It is desirable for a pessary to be able to treat all the common forms of vaginitis, which are most often caused by infection with Candida albicans, Trichomonas vaginalis or Gardnerella sp, either singly or mixed. Commonly derivatives of imidazole and nitroimidazole are used to treat such conditions, examples of such drugs being miconazole, clotrimazole, ornidazole, tinidazole and metronidazole, but despite the good activity of these compounds none has so far individually achieved the broad spectrum of activity required to combat all the common types of infection. Other types of drugs used in such infections include nitrofurfuryl derivatives and various antibiotics.
While such drugs have been formulated as pessaries and vaginal tablets, it has been found for metronidazole that the relapse rate with trichomonal infections (i.e. the rate of reappearance of infection after cessation of the medicament) is higher when administered in this way than when administration is by the oral route. Consequently the oral route is now the preferred route for administration of metronidazole, and pessaries containing this compound have been virtually discontinued. This results in mixed vaginal infections being treated by both the oral and vaginal routes, with consequent inconvenience to the patient.
However, the half life of most anti-vaginitis medicaments is generally relatively short, for example six hours, and it is difficult to formulate a medicament which can effectively be administered only once a day. On the other hand, when starting administration, it is preferable to provide a relatively large booster dose of the active substance, so that a delayed release formulation is not entirely satisfactory. Similarly, even when using delayed release, levels of the active substance tend to fall towards the end of the period, for example 24 hours, so that a booster dose may be desirable at intervals during medication.
We have found that it is possible to reconcile the above requirements by providing multiphase formulations comprising a continuous phase containing a relatively large amount of one or more anti-vaginitis medicaments for relatively rapid initial release and containing, dispersed therein, microporous particles containing one or more of the anti-vaginitis medicaments and releasing these over a prolonged period, for example 24 hours.
According to the present invention we provide a pharmaceutical composition for the treatment of vaginitis comprising a continuous phase containing one or more anti-vaginitis medicaments for rapid release and porous particles dispersed therein adapted for delayed release of one or more anti-vaginitis medicaments.
In one embodiment of the invention we provide a cream containing the anti-vaginitis medicament(s) together with porous particles containing one or more of anti-vaginitis medicaments.
The phase in which the medicament(s) are contained may be a conventional cream base, e.g. containing oily or waxy materials such as liquid paraffin, white petroleum or cetyl alcohol, water and one or more surfactants to produce a water-in-oil emulsion. A bactericide such as benzalkonium chloride is conveniently present.
According to a further embodiment of the invention, the compositions take the form of pessaries comprising a pessary base containing the anti-vaginitis medicament(s) and porous particles for delayed release of anti-vaginitis medicament(s).
The pessary base may be of any conventional material for vaginal administration such as glycerol/gelatin glyco-gelatin, macrogols (polyethylene glycols), natural, synthetic or semisynthetic hard fats, and fractionated palm kernel oil. A particularly preferred material is a hard fat such as cocoa butter (theobroma oil), for instance the range of cocoa butter-based products sold under the trade name Witepsol by Dynamit Nobel, Slough, England.
The pessary base may conveniently contain a surfactant to promote dispersal of the active substances. It may also be advantageous to include a surfactant in the porous particles to aid release of the medicament therein and to promote continuous penetration of the active substances into the mucosal folds.
The surfactant may be a cationic, non-ionic, anionic or amphoteric surfactant although non-ionic surfactants are preferred. Anionic surfactants include salts of long chain alkyl sulphonate esters such as sodium lauryl sulphate, sodium cetostearyl sulphate and sodium tetradecyl sulphate; salts of long chain carboxylic acids such as stearates.
Cationic surfactants include quaternary ammonium or pyridinium compounds such as benzalkonium chloride (a mixture of benzyl alkyl dimethyl chlorides, the alkyl chain ranging from C8 to C18), tetradecyltrimethyl ammonium bromide and cetylpyridinium chloride.
Amphoteric surfactants include lauryl 1-carboxy glycine and lecithins such as soya lecithin.
Non-ionic surfactants include glycol and glycerol esters such as glyceryl monostearate; macrogol esters and ethers such as cetomacrogol; sorbitan and mannitan esters such as sorbitan tristearate; and polyoxyethylene derivatives of such sorbitan esters, for instance polyoxyethylene (20) sorbitan mono-oleate.
The level of surfactant required in the pessary formulation will be readily determined by those skilled in the art and will depend on the specific surfactant and the nature of the pessary base; conveniently it is in the range 0.1 to 10 percent by weight, preferably 1 to 5 percent.
It is especially preferred to use a cetomacrogol surfactant in conjunction with a cocoa-butter base such as Witepsol. In such a formulation the surfactant is suitably present in the range 1 to 5 percent by weight, for instance about 40 mg in an overall pessary weight of 2540 mg (including active ingredients).
In general, the active substances should include at least one medicament active against Trichomonas vaginalis.
Thus one aspect of the invention provides a pessary for human administration comprising an effective amount of one or more drugs active against Trichomonas vaginalis, a pessary base and a surfactant.
The preferred antitrichomonal drug is metronidazole.
The use of a surfactant according to the invention allows the active antitrichomonal drug fully to penetrate between the apposed layers of vaginal epithelium which occur in the rugose surface of the vagina so reaching the Trichomonas sp. which otherwise would be protected by such apposition from contact with the active ingredients of conventional pessary formulations. The relapse rate when treatment ceases can therefore be expected to be lower than when metronidazole is administered intravaginally in a conventional pessary formulation.
In order to produce a broad spectrum of activity against vaginal infections, it is desirable to include one or more drugs active against Candida albicans and/or Gardnerella sp. This is particularly desirable since administration of metronidazole alone sometimes results in proliferation of infecting fungal pathogens. A fungicidally active derivative of nitroimdazole such as butoconazole or, more preferably, miconazole, is advantageously used as the drug active against Candida albicans. Ornidazole, Ketoconazole, Tioconazole and Tinidazole are also suitable fungicidally active agents. Where metronidazole is used as the antitrichomonal drug, it will also be effective against Gardnerella sp. However, a broad spectrum antibiotic such as pivampicillin or Clindamycin may advantageously also be included. In order to counter the inflammation and itching associated with vaginitis, it may be beneficial to include a steroidal or non-steroidal antiinflammatory drug such as hydrocortisone or ibuprofen. Lactic acid may also advantageously be included as a further active ingredient.
The pessaries of the present invention may also advantageously include chlorophyll as a deodorant. We have found that although some staining of clothes by the green coloration of the chlorophyll may take place, the surfactant in the composition ensures that such stains are readily removed.
The quantity of metronidazole is conveniently from 500 to 1500 mg per pessary, more preferably from 800 to 1200 mg and suitably about 1000 mg.
The pessary may conveniently contain from 200 to 600 mg of miconazole, more preferably from 240 to 480 mg. The miconazole may be in the form of the free base, especially in the porous particles, or as a salt, for instance the nitrate, especially in the pessary base--a suitable quantity of miconazole per pessary is then about 400 mg.
The porous particles containing anti-vaginitis medicaments may contain two or more such medicaments and/or the composition may contain mixtures of porous particles each containing a different medicament or mixtures of medicaments.
A wide range of porous particles are available, as described in International Patent Applications WO88/01164 and WO89/10132, U.S. Pat. Nos. 4,873,091 and 4,690,825 and EP-A-306236, the contents of which are incorporated herein by reference.
In such porous particles, the total pore volume is preferably in the range 0.1 to 2.0 ml/g, more preferably 0.3 to 1.0 ml/g. The diameters of the particles will generally be in the range 1 to 1000 microns, preferably 5 to 100 microns, more preferably 10 to 50 microns: the surface area of the particles will generally range from about 1 to 500 m2 /g, preferably 20 to 200 m2 /g.
The porous particles may be composed of a wide range of materials. Many organic, synthetic polymers are suitable, as well as natural substances such as cellulose or gelatin. The choice of material will depend in part on the intended means of delayed release of the active medicament, i.e. diffusion, compression, dissolving or melting.
Where diffusion of the active medicament is intended, the porous particles may be relatively rigid. This has the advantage that the outermost pores do not collapse when the medicament diffuses out and thus do not block the diffusion of the medicament from the inner pores. Such rigidity can be controlled by the degree of cross-linking of polymeric materials of which the particles are composed. The degree of cross-linking will generally be at least 10%, more usually in the range 20 to 80%, for example 25 to 60%.
Polymers of which the particles may be formed include polyolefins, including polyethylene, polystyrene, polydicyclopentadiene etc.; polyacrylate esters, e.g. optionally alkoxylated C1-10 alkyl, cycloalkyl, aryl or aralkyl esters of polyacrylic or polymethacrylic acids; polyvinyl esters e.g. polyvinyl acetate or polyvinyl laurate; polyvinyl ketones, e.g. polyvinylmethyl ketone; and polyvinyl ethers, e.g. polyvinylpropyl ether.
As indicated above, the porous particles in such a cream may liberate the active medicament by diffusion, pressure, dissolving or melting. It is preferred that the particles are elastically compressable so that after first application of the cream whereby the medicament contacts the infected area, application of gentle pressure, for example by rubbing, causes rapid release of the active medicament to provide a coating of medicament over the layer of cream.
Elastically compressable particles may be composed of elastomers, such as those described in U.S. Pat. No. 4,873,091, including for example, isoprene rubbers, butadiene rubbers, chloroprene rubbers, styrene butadiene. Particularly useful are ethylene-propylene-diene terpolymers, wherein the diene components may be straight chain diolefins, cyclic dienes and bicyclic dienes. Examples of such dienes include 1,4-hexadiene, dicyclopentadiene and ethylidene norbornene. Silicone rubbers may also be used.
Porous particles which dissolve, primarily in aqueous body fluids, may be composed of water-soluble gels including gelatin, agarose etc and certain polymethyl methacrylates such as Eudragit (Rohm, Darmstadt) which dissolve at the pH of the vagina.
Porous particles which melt may be composed of fats and waxes of the type used in suppositories which melt at body temperatures but which are solid at room temperature as well as gelatin.
Porous materials for use in compositions of the invention may be made in any convenient way. Thus, it is possible to polymerise one or more suitable monomers in the presence of a dispersed porogen: after polymerisation, the porogen may be removed, e.g. by evaporation or solvent extraction, to provide a network of interconnected pores. The active medicament can then be absorbed into the porous material, if desired by first evacuating air from the pores. The active medicament can, however, itself be used as the porogen: the medicament may be dispersed in droplets through a monomer with which it is immiscible so that after polymerisation the active medicament effectively fills pores within the polymeric material. In general, however, it is preferred to prepare the porous material first in order to remove rigorously all traces of monomer, catalysts and cross-linking agents, before introduction of active medicament.
A number of possible methods of manufacture of porous material, in particular porous particles, are described in the prior patents listed above.
In general, porous particles may conveniently be produced by emulsion or suspension polymerisation in a liquid--liquid system. Thus, for example, a solution comprising the chosen water-immiscible monomer, any cross-linking agent required, a catalyst, if needed, and a porogen which is miscible with the solution but immiscible with water. The solution is then suspended in an aqueous solution, which may contain one or more suspending agents or surfactants and polymerisation is initiated e.g. by raising the temperature or by irradiation. The porogen is then removed from the solidified particles, e.g. by evaporation or extraction into a solvent which is substantially inert to the polymer.
Examples of such porogens include C5-12 alkanes, C5-8 cycloalkanes and aromatic solvents such as benzene toluene etc. The particles will normally be washed thoroughly to remove contaminants, using solvents such that the final solvent can be removed by evaporation.
In general, particle diameter may be controlled by the degree of agitation to prepare the initial emulsion. The pore diameter and pore volume are controlled by the amount of porogen used and the degree of cross-linking.
The monomers used to prepare the particles may be any of those appropriate to make the polymers set out above. Suitable cross-linking agents for mono-olefins include poly-ethylenically unsaturated monomers.
The dosage of active medicament(s) contained in the porous particles will vary with the individual medicaments and their half-lives. In general, the ratio of delayed release medicament to rapid release medicament is preferably in the range 1:1 to 5:1, for example 2:1 to 4:1.
The porous particles may be evenly distributed throughout the composition or, in the case of pessaries, may be concentrated in one or more zones, for example in a core.
In general, the size of the porous particles is preferably such that they cannot be taken up into the lymph ducts. On the other hand, large particles give a gritty effect which may produce discomfort. In general, the preferred size range for the porous particles is 10-100 microns.
The following Examples are given by way of illustration only:
EXAMPLE 1
Pessary
Composition of Pessary base
______________________________________                                    
Metronidazole   250.0 mg                                                  
Miconazole nitrate                                                        
                50.0 mg                                                   
Witepsol w35    1745.4 mg                                                 
Cetomacrogol    34.6 mg                                                   
                2080.0 mg                                                 
                per pessary                                               
______________________________________
Composition of Microsponges
______________________________________                                    
Metronidazole      500.0 mg                                               
Miconazole         100.0 mg                                               
both held within polystyrene-                                             
divinylbenzene porous beads,                                              
pore volume 0.5 ml/g                                                      
______________________________________
Method of Manufacture
The two active ingredients and the surfactant of the base are mixed into the molten Witepsol w35 and the resulting mixture is blended with the pre-prepared porous beads before being poured into pre-cooled moulds. The moulds are passed through a cooling tunnel at -10° C., the pessaries are removed from the moulds and packaged. 0.1% by weight of chlorophyl may be added to both base and microsponge phases.
EXAMPLE 2
Pessary
Composition of Pessary Base
______________________________________                                    
Polyethylene glycol 4000                                                  
                  900.0 mg                                                
Polyethylene glycol 1000                                                  
                  450.0 mg                                                
Polyethylene glycol 400                                                   
                  118.5 mg                                                
MONATERIC 951A     42.0 mg                                                
metronidazole     250.0 mg                                                
Tioconazole hydrochloride                                                 
                  100.0 mg                                                
pivanpicillin     100.0 mg                                                
                  1960.5 mg                                               
                  per pessary                                             
______________________________________
MONATERIC is a surfactant available from Mono Industries Ltd., Paterson, N.J., U.S.A.
Composition of Porous Beads
______________________________________                                    
Metronidazole        500.0 mg                                             
Tioconazole          200.0 mg                                             
Hydrocortisone        50.0 mg                                             
Pivampicillin         50.0 mg                                             
blended together and held within                                          
a polystyrenedivinylbenzene                                               
porous beads, pore volume 0.5 ml/g                                        
______________________________________
The pessary is prepared according to the method of Example 1. The MONATERIC 951A may be replaced by MONAQUAT PT-C, PT-L, PT-S or Phospholipid EFA.
EXAMPLE 3
Pessary
______________________________________                                    
Polystyrene-divinylbenzene porous                                         
                      25 g                                                
beads (mean particle diameter 30                                          
microns, pore volume 0.5 ml/g)                                            
containing 2 g miconazole and 10 g                                        
metronidazole                                                             
50% Benzalkonium chloride                                                 
                     0.2 g                                                
Hydrocortisone acetate                                                    
                     0.5 g                                                
Metronidazole        12.5 g                                               
Miconazole           2.5 g                                                
Witepsol S55 suppository base                                             
                     63.65 g                                              
Witepsol E85 suppository base                                             
                     10.65 g                                              
______________________________________
The above components apart from the porous particles containing their active ingredients are blended at 55° C., cooled to 40° C. and poured into 50 moulds with central pins to make the pessaries formed hollow. After cooling, the pins are withdrawn, the moulds are inverted and porous particles introduced into the cavity left by each pin. The remainder of the cavity is filled with a blend of the two Witepsol bases at 40° C. After chilling, the pessaries are removed from the moulds and packaged.
EXAMPLE 4
Cream
______________________________________                                    
                    %                                                     
______________________________________                                    
Polystyrene-divinylbenzene porous                                         
                      25.0                                                
beads (mean particle diameter 30                                          
microns, pore volume 0.5 ml/g)                                            
containing 2 g miconazole and 10 g                                        
metronidazole                                                             
Liquid paraffin       17.75                                               
White petrolatum      8.0                                                 
Cetyl alcohol         7.0                                                 
Span 60               3.0                                                 
Miconazole            0.5                                                 
Metronidazole         2.0                                                 
Potassium dihydrogen phosphate                                            
                      0.5                                                 
1% Aqueous Benzalkonium chloride                                          
                      10.0                                                
Tween 60              5.0                                                 
70% Aqueous sorbitol  5.0                                                 
Hydrocortisone acetate                                                    
                      0.5                                                 
Water                 15.75                                               
______________________________________
The oily phase comprising the liquid paraffin, white petrolatum, cetyl alcohol and Span 60 are mixed at 60° C. The aqueous phase comprising the remaining components except the porous beads is also blended at 60° C. and the two phases combined and homogeneously blended. The porous beads are added subsequently and dispersed throughout the cream.
EXAMPLE 5
Pessary
Composition of Pessary Base
______________________________________                                    
Metronidazole   250.0 mg                                                  
Miconazole nitrate                                                        
                50.0 mg                                                   
Witepsol w35    1745.4 mg                                                 
Cetomacrogol    34.6 mg                                                   
                2080.0 mg                                                 
                per pessary                                               
______________________________________
Composition of Microsponges
______________________________________                                    
Metronidazole      500.0 mg                                               
Miconazole         100.0 mg                                               
Sorbitan mono-oleate                                                      
                   190.0 mg                                               
each held within polystyrene-                                             
divinylbenzene porous beads,                                              
pore volume 0.5 ml/g                                                      
______________________________________
The pessary is prepared according to the method of Example 1.

Claims (13)

We claim:
1. A multi-phase pharmaceutical composition for topical administration in the form of a cream or pessary for the treatment of vaginitis comprising a continuous phase containing two or more anti-vaginitis medicaments for rapid initial release and dispersed therein porous particles adapted for the delayed release of two or more anti-vaginitis medicaments, and wherein the medicaments for both rapid and delayed release are metronidazole together with one or more drugs active against Candida albicans and /or Gardneralla sp.
2. A composition as claimed in claim 1 further comprising a surfactant.
3. A composition as claimed claim 1 in the form of a cream.
4. A composition as claimed claim 1 in the form of a pessary.
5. A pharmaceutical composition as claimed in claim 1 wherein the ratio of delayed release medicament to rapid initial release medicament is in the range 1:1 to 5:1.
6. A composition as claimed in claim 5 wherein the ratio is in the range 2:1 to 4:1.
7. A pharmaceutical composition as claimed in claim 4 wherein the pessary comprises a core in which the porous particles are concentrated.
8. A composition as claimed in claim 4 wherein the continuous phase comprises about 250 mg of metronidazole and about 50 mg of miconazole nitrate as active ingredients, and wherein the porous particles comprise about 500 mg of metronidazole and about 100 mg of miconazole nitrate as active ingredients.
9. A composition as claimed in claim 4 wherein the continuous phase comprises about 250 mg of metronidazole, about 100 mg of tioconazole hydrochloride, and about 100 mg of pivampicillin as active ingredients, and wherein the porous particles comprise about 500 mg of metronidazole, about 200 mg of tioconazole hydrochloride, about 50 mg of hydrocortisone, and about 50 mg of pivampicillin as active ingredients.
10. A composition as claimed in claim 2, wherein the surfactant is a cetomacrogol surfactant and the composition contains a pessary base which is a hard fat cocoa-butter.
11. A composition as claimed in claim 1 wherein said medicaments are metronidazole and miconazole.
12. A composition as claimed in claim 1 which additionally includes one or more medicaments selected from a broad spectrum antibiotic, an anti-inflammatory drug and a bactericide.
13. A method of treatment of vaginitis, said method comprising administering intravaginally a composition as claimed in claim 1.
US08/605,070 1993-09-08 1994-09-08 Multi-phase compositions for an initial and delayed release of a vaginal medicament Expired - Fee Related US5985319A (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GB939318641A GB9318641D0 (en) 1993-09-08 1993-09-08 Compositions
GB9318641 1993-09-08
PCT/GB1994/001950 WO1995007071A1 (en) 1993-09-08 1994-09-08 Multi-phase compositions for an initial and delayed release of a medicament

Publications (1)

Publication Number Publication Date
US5985319A true US5985319A (en) 1999-11-16

Family

ID=10741718

Family Applications (1)

Application Number Title Priority Date Filing Date
US08/605,070 Expired - Fee Related US5985319A (en) 1993-09-08 1994-09-08 Multi-phase compositions for an initial and delayed release of a vaginal medicament

Country Status (5)

Country Link
US (1) US5985319A (en)
EP (1) EP0717615B1 (en)
DE (1) DE69426454D1 (en)
GB (1) GB9318641D0 (en)
WO (1) WO1995007071A1 (en)

Cited By (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2002003896A1 (en) * 2000-07-11 2002-01-17 Umd, Inc. Device and method for intravaginal or transvaginal treatment of fungal, bacterial, viral or parasitic infections
US20040033968A1 (en) * 2002-08-16 2004-02-19 Lin Shun Y. Optimal volume of intra-vaginal semisolid dosage forms for treating vaginal infections
RU2237476C1 (en) * 2003-02-13 2004-10-10 Открытое акционерное общество "Химико-фармацевтический комбинат "Акрихин" Fungicidal pharmaceutical composition
US20050095245A1 (en) * 2003-09-19 2005-05-05 Riley Thomas C. Pharmaceutical delivery system
US6897271B1 (en) * 2000-01-05 2005-05-24 Novartis Ag Porous hydrogels
US20060140990A1 (en) * 2003-09-19 2006-06-29 Drugtech Corporation Composition for topical treatment of mixed vaginal infections
US20070110805A1 (en) * 2005-05-09 2007-05-17 Levinson R S Modified-release pharmaceutical compositions
US20070154516A1 (en) * 2006-01-05 2007-07-05 Drugtech Corporation Drug delivery system
US20070160668A1 (en) * 2001-07-23 2007-07-12 Bioalliance Pharma Prolonged release bioadhesive therapeutic systems
US20070224226A1 (en) * 2006-01-05 2007-09-27 Drugtech Corporation Composition and method of use thereof
US20090143477A1 (en) * 1999-04-28 2009-06-04 Regents Of The University Of Michigan Antimicrobial Nanoemulsion Compositions and Methods
US20120165302A1 (en) * 2002-10-24 2012-06-28 Goldstein Jay A Antifungal formulations
US8747896B2 (en) 2006-03-24 2014-06-10 Bioalliance Pharma Mucosal bioadhesive slow release carrier for delivering active principles

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9610359D0 (en) * 1996-05-17 1996-07-24 Edko Trading Representation Pharmaceutical compositions
KR100494277B1 (en) * 1996-05-17 2005-08-05 에드코 트래이딩 앤드 레프리젠테이션 캄파니 리미티드 Anti-Vaginitis Composition for Topical Use Comprising One or More Anti-Vaginitis Medicaments and One or More Local Anaesthetics
EP1611878A1 (en) * 1997-01-24 2006-01-04 FemmePharma Holding Company, Inc. Pharmaceutical preparations and methods for their regional administration
US5993856A (en) * 1997-01-24 1999-11-30 Femmepharma Pharmaceutical preparations and methods for their administration
US6416778B1 (en) 1997-01-24 2002-07-09 Femmepharma Pharmaceutical preparations and methods for their regional administration
JP2005513080A (en) 2001-12-20 2005-05-12 フェムファーマ， インコーポレイテッド Vaginal delivery of drugs
US9173836B2 (en) 2003-01-02 2015-11-03 FemmeParma Holding Company, Inc. Pharmaceutical preparations for treatments of diseases and disorders of the breast
AU2004203700B2 (en) 2003-01-02 2007-06-21 Femmepharma Holding Company, Inc. Pharmaceutical preparations for treatments of diseases and disorders of the breast
US20050214364A1 (en) * 2004-03-23 2005-09-29 Hutman Herbert W Products and methods for treating vaginal infections
EP2354128A1 (en) * 2010-02-10 2011-08-10 Sandoz Ag Method for the preparation of rivaroxaban
WO2014026707A1 (en) * 2012-08-13 2014-02-20 Edko Pazarlama Tanitim Ticaret Limited Sirketi Anti-vaginitis compositions with improved release and adherence

Citations (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4690825A (en) * 1985-10-04 1987-09-01 Advanced Polymer Systems, Inc. Method for delivering an active ingredient by controlled time release utilizing a novel delivery vehicle which can be prepared by a process utilizing the active ingredient as a porogen
US4713247A (en) * 1983-06-15 1987-12-15 Shionogi & Co., Ltd. Long-acting formulation of cefaclor
US4873091A (en) * 1988-05-23 1989-10-10 Advanced Polymer Systems, Inc. Controlled release formulating employing resilient microbeads
WO1990007325A1 (en) * 1988-12-30 1990-07-12 Edko Trading And Representation Company Limited A pessary containing antibacterial drugs
EP0388718A2 (en) * 1989-03-20 1990-09-26 Advanced Polymer Systems, Inc. Fabric impregnated with functional substances for controlled release
US5045082A (en) * 1990-01-10 1991-09-03 Alza Corporation Long-term delivery device including loading dose
EP0486117A1 (en) * 1990-06-28 1992-05-20 EDKO Trading and Representation Co., Ltd Multiphase pharmaceutical formulations
WO1992010998A1 (en) * 1990-12-21 1992-07-09 Felice Bombart Aqueous vaginal douche and related methods

Patent Citations (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4713247A (en) * 1983-06-15 1987-12-15 Shionogi & Co., Ltd. Long-acting formulation of cefaclor
US4690825A (en) * 1985-10-04 1987-09-01 Advanced Polymer Systems, Inc. Method for delivering an active ingredient by controlled time release utilizing a novel delivery vehicle which can be prepared by a process utilizing the active ingredient as a porogen
US4873091A (en) * 1988-05-23 1989-10-10 Advanced Polymer Systems, Inc. Controlled release formulating employing resilient microbeads
WO1990007325A1 (en) * 1988-12-30 1990-07-12 Edko Trading And Representation Company Limited A pessary containing antibacterial drugs
EP0388718A2 (en) * 1989-03-20 1990-09-26 Advanced Polymer Systems, Inc. Fabric impregnated with functional substances for controlled release
US5045082A (en) * 1990-01-10 1991-09-03 Alza Corporation Long-term delivery device including loading dose
EP0486117A1 (en) * 1990-06-28 1992-05-20 EDKO Trading and Representation Co., Ltd Multiphase pharmaceutical formulations
WO1992010998A1 (en) * 1990-12-21 1992-07-09 Felice Bombart Aqueous vaginal douche and related methods

Cited By (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6416779B1 (en) * 1997-06-11 2002-07-09 Umd, Inc. Device and method for intravaginal or transvaginal treatment of fungal, bacterial, viral or parasitic infections
US20090143477A1 (en) * 1999-04-28 2009-06-04 Regents Of The University Of Michigan Antimicrobial Nanoemulsion Compositions and Methods
US8236335B2 (en) * 1999-04-28 2012-08-07 The Regents Of The University Of Michigan Antimicrobial nanoemulsion compositions and methods
US6897271B1 (en) * 2000-01-05 2005-05-24 Novartis Ag Porous hydrogels
WO2002003896A1 (en) * 2000-07-11 2002-01-17 Umd, Inc. Device and method for intravaginal or transvaginal treatment of fungal, bacterial, viral or parasitic infections
CN1306919C (en) * 2000-07-11 2007-03-28 Umd公司 Device and method for intravaginal or transvaginal treatment of fungal, bacterial, viral or parasitic infections
US20110039800A1 (en) * 2001-07-23 2011-02-17 Jean-Marc Aiache Prolonged release bioadhesive therapeutic systems
US8518442B2 (en) 2001-07-23 2013-08-27 BioAlliance Pharma, S.A. Prolonged release bioadhesive therapeutic systems
US20070160668A1 (en) * 2001-07-23 2007-07-12 Bioalliance Pharma Prolonged release bioadhesive therapeutic systems
US20040033968A1 (en) * 2002-08-16 2004-02-19 Lin Shun Y. Optimal volume of intra-vaginal semisolid dosage forms for treating vaginal infections
US20120165302A1 (en) * 2002-10-24 2012-06-28 Goldstein Jay A Antifungal formulations
RU2237476C1 (en) * 2003-02-13 2004-10-10 Открытое акционерное общество "Химико-фармацевтический комбинат "Акрихин" Fungicidal pharmaceutical composition
US20050095245A1 (en) * 2003-09-19 2005-05-05 Riley Thomas C. Pharmaceutical delivery system
US20060140990A1 (en) * 2003-09-19 2006-06-29 Drugtech Corporation Composition for topical treatment of mixed vaginal infections
US9789057B2 (en) 2003-09-19 2017-10-17 Perrigo Pharma International Designated Activity Company Pharmaceutical delivery system
US20070110805A1 (en) * 2005-05-09 2007-05-17 Levinson R S Modified-release pharmaceutical compositions
US20070224226A1 (en) * 2006-01-05 2007-09-27 Drugtech Corporation Composition and method of use thereof
US20070154516A1 (en) * 2006-01-05 2007-07-05 Drugtech Corporation Drug delivery system
US8747896B2 (en) 2006-03-24 2014-06-10 Bioalliance Pharma Mucosal bioadhesive slow release carrier for delivering active principles
US8791127B2 (en) 2006-03-24 2014-07-29 Bioalliance Pharma Mucosal bioadhesive slow release carrier for delivering active principles

Also Published As

Publication number Publication date
DE69426454D1 (en) 2001-01-25
WO1995007071A1 (en) 1995-03-16
EP0717615A1 (en) 1996-06-26
EP0717615B1 (en) 2000-12-20
GB9318641D0 (en) 1993-10-27

Similar Documents

Publication Publication Date Title
US5985319A (en) Multi-phase compositions for an initial and delayed release of a vaginal medicament
RU2195281C2 (en) Antivaginitis composition for topical application comprising one or more antivaginitis medicinal agents and one or more topical anesthetics
EP0325843B1 (en) Pharmaceutical formulations for preventing drug tolerance
Thombre et al. Delivery of glipizide from asymmetric membrane capsules using encapsulated excipients
CA2181693C (en) Device for administration of beneficial materials to ruminants
AU735815B2 (en) Composition for suppositories
MXPA06000408A (en) Delivery of an active drug to the posterior part of the eye via subconjuctival or periocular delivery of a prodrug.
FI85105C (en) suppository
JPH0725676B2 (en) Therapeutic formulation containing pseudoephredine and brompheniramine
DE3400106A1 (en) Pharmaceutical compositions with controlled release of medicinal substance
EP0486117B1 (en) Multiphase pharmaceutical formulations
KR100494277B1 (en) Anti-Vaginitis Composition for Topical Use Comprising One or More Anti-Vaginitis Medicaments and One or More Local Anaesthetics
KR100450330B1 (en) Base for suppository
WO1990007325A1 (en) A pessary containing antibacterial drugs
CA2388471A1 (en) Pharmaceutical carrier formulation
JPH05504935A (en) drug prescription
KR100733028B1 (en) Preparation for rectal administration
EP0608306B1 (en) Peroral drug delivery system
CA2006978A1 (en) Pharmaceutical formulation
JP2002515047A (en) New method
CA2058263A1 (en) Pharmaceutical formulations
Khohlokwane Microencapsulation of an antiplatelet agent
JP2003238397A (en) Therapeutic agent of hemorrhoid
IE940446A1 (en) Controlled release formulation

Legal Events

Date Code Title Description
AS Assignment

Owner name: EDKO TRADING AND REPRESENTATION COMPANY LIMITED, T

Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNORS:EMBIL, KORAL;MORTON, OSWALD;REEL/FRAME:007926/0505

Effective date: 19960404

REMI Maintenance fee reminder mailed
LAPS Lapse for failure to pay maintenance fees
FP Lapsed due to failure to pay maintenance fee

Effective date: 20031116

STCH Information on status: patent discontinuation

Free format text: PATENT EXPIRED DUE TO NONPAYMENT OF MAINTENANCE FEES UNDER 37 CFR 1.362